{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05854381",
            "orgStudyIdInfo": {
                "id": "VIR-1388-V101"
            },
            "secondaryIdInfos": [
                {
                    "id": "5UM1AI068614-18",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/5UM1AI068614-18"
                }
            ],
            "organization": {
                "fullName": "Vir Biotechnology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV",
            "officialTitle": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants With Overall Good Health and Without HIV",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "to-investigate-safety-reactogenicity-and-immunogenicity-of-vir-compared-with-placebo-in-participants-without-hiv"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-12",
            "studyFirstSubmitQcDate": "2023-05-02",
            "studyFirstPostDateStruct": {
                "date": "2023-05-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-14",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vir Biotechnology, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Institute of Allergy and Infectious Diseases (NIAID)",
                    "class": "NIH"
                },
                {
                    "name": "HIV Vaccine Trials Network",
                    "class": "NETWORK"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.",
            "detailedDescription": "This is a Phase 1, randomized, double-blind, placebo-controlled, multicenter study in adults aged 18 to 55 years in overall good health and without HIV. Participants will be enrolled concurrently into 1 of 3 dose levels of VIR-1388 or placebo. The overall study design includes 2 study parts, Part A and Part B. Part A will be a lead-in phase enrolling a limited number of HCMV seropositive persons of non-childbearing potential (PONCBP) with a frequent safety monitoring schedule. Part B will expand enrollment into a broader population of HCMV-seropositive participants, including persons of childbearing potential required to use 2 forms of contraception and maintains a similar overall safety monitoring schedule as Part A . There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose."
        },
        "conditionsModule": {
            "conditions": [
                "HIV I Infection"
            ],
            "keywords": [
                "HIV",
                "Vaccine",
                "CMV",
                "Cytomegalovirus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 95,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "VIR-1388, 5\u00d710^4 ffu",
                    "type": "EXPERIMENTAL",
                    "description": "Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.",
                    "interventionNames": [
                        "Biological: VIR-1388"
                    ]
                },
                {
                    "label": "VIR-1388, 5\u00d710^5 ffu",
                    "type": "EXPERIMENTAL",
                    "description": "Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.",
                    "interventionNames": [
                        "Biological: VIR-1388"
                    ]
                },
                {
                    "label": "VIR-1388, 5\u00d710^6 ffu",
                    "type": "EXPERIMENTAL",
                    "description": "Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.",
                    "interventionNames": [
                        "Biological: VIR-1388"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.",
                    "interventionNames": [
                        "Biological: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "VIR-1388",
                    "description": "VIR-1388 is given by subcutaneous injection",
                    "armGroupLabels": [
                        "VIR-1388, 5\u00d710^4 ffu",
                        "VIR-1388, 5\u00d710^5 ffu",
                        "VIR-1388, 5\u00d710^6 ffu"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Placebo",
                    "description": "The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of unsolicited, treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), new-onset chronic diseases (NOCDs) and medically attended adverse events (MAAEs)",
                    "description": "Events will be graded as per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Incidence of solicited local site and systemic reactogenicity events",
                    "description": "Events will be graded as per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017",
                    "timeFrame": "14 days after administration of each dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Frequency of HIV-1 Mfuse1-specific CD4 T cells",
                    "description": "As measured by intracellular cytokine staining (ICS) and flow cytometry",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Frequency of HIV-1 Mfuse1-specific CD8 T cells",
                    "description": "As measured by intracellular cytokine staining (ICS) and flow cytometry",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Memory phenotype of HIV-1 Mfuse1-specific CD4 T cells",
                    "description": "As determined by flow cytometry analysis",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Memory phenotype of HIV-1 Mfuse1-specific CD8 T cells",
                    "description": "As determined by flow cytometry analysis",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Number of participants with VIR-1388 vector viremia in plasma",
                    "description": "Detected by quantitative polymerase chain reaction(qPCR) of plasma",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Number of participants with VIR-1388 vector shedding in saliva and urine",
                    "description": "Detected by quantitative polymerase chain reaction(qPCR) of saliva and urine",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* In overall good health as determined by medical history, physical exam, and laboratory values\n* HIV uninfected\n* CMV seropositive\n* Willing to use condoms during intercourse for the duration of the study\n* Assessed by clinic staff as being low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last protocol visit\n* Childbearing status\n\n  * Part A: Only participants of non-childbearing potential\n  * Part B: Participants of childbearing potential must be on 2 forms of contraception and not planning on becoming pregnant for the duration of the study\n\nExclusion Criteria:\n\n* Participant is immunocompromised\n* Participant has an autoimmune disorder\n* Immunocompromised individuals\n* Participants having intimate contact with immunocompromised individuals\n* Participants having intimate contact with a pregnant partner or partner planning to become pregnant\n* Participants who are breastfeeding",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Inquiry",
                    "role": "CONTACT",
                    "phone": "+1 415-654-5281",
                    "email": "clinicaltrials@vir.bio"
                }
            ],
            "locations": [
                {
                    "facility": "Alabama CRS",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35222",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Paul Goepfert, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "The Hope Clinic of the Emory Vaccine Center CRS",
                    "status": "RECRUITING",
                    "city": "Decatur",
                    "state": "Georgia",
                    "zip": "30030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.77483,
                        "lon": -84.29631
                    }
                },
                {
                    "facility": "Beth Israel Deconess Medical Center VCRS",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "32077",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kathryn Stephenson, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Penn Prevention CRS",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ian Frank, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "University of Pittsburgh CRS",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharon Riddler, MD MPH",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Seattle Vaccine and Prevention CRS",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie McElrath, MD PhD MPH",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Perinatal HIV Research Unit",
                    "status": "RECRUITING",
                    "city": "Soweto",
                    "state": "Gauteng",
                    "zip": "1862",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Fatima Laher, MBBCh DipHIVMan",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -26.26781,
                        "lon": 27.85849
                    }
                },
                {
                    "facility": "Isipingo Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Isipingo",
                    "state": "Kwa-Zulu Natal",
                    "zip": "4110",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Dishiki Jenny Kalonji, MBBCh FCPHM MMed",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -29.98639,
                        "lon": 30.91853
                    }
                },
                {
                    "facility": "Chatsworth Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Overport",
                    "state": "Kwa-Zulu Natal",
                    "zip": "4092",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Logashvari Naidoo, MBChB",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -29.8348,
                        "lon": 31.00012
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "T8",
                    "name": "Histidine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}